IHT

IHT (Iberhospitex) is a European medical technology company specializing in the development, manufacture, and commercialization of high-value products for interventional cardiology and advanced wound care. Founded in 1980 and headquartered in Barcelona, the company has established itself as a pioneer in drug-eluting technologies, notably with its sirolimus-eluting coronary stent systems. IHT's business is divided into two primary pillars: a cardiology division focused on minimally invasive cardiovascular treatments and a hospital division dedicated to skin and wound management. The company leverages proprietary biomaterials and drug-delivery platforms to create innovative solutions such as drug-eluting dressings and advanced surgical textiles. With a strong international presence through subsidiaries in France, Poland, and beyond, IHT continues to expand its portfolio of clinically proven medical devices to improve patient outcomes globally.